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Abstract
Aims/hypothesis The aim of this work was to assess whether
neonatal levels of 25-hydroxyvitamin D (25(OH)D) are asso-
ciated with risk of developing type 1 diabetes before the age of
18 years.
Methods Two large-scale studies with different de-
signs—a case-cohort and a case–control—were con-
ducted using Danish national register data and biobank
material. Weighted Cox regression and conditional lo-
gistic regression were used to calculate HRs and ORs,
respectively. The concentration of 25(OH)D was
assessed from neonatal dried blood spots using highly
sensitive liquid chromatography–tandem mass spec-
trometry. Quintiles of 25(OH)D3 were used in the main
analyses.
Results The case-cohort study included 912 type 1 diabetes
cases and 2866 individuals without type 1 diabetes born in
Denmark between 1981 and 2002 and followed up until the
end of 2012. The case–control study included 527 matched
case–control pairs born between 1981 and 1999 and followed
up until May 2004. Both studies found no association between
25(OH)D3 levels and later risk of developing type 1 diabetes.
The neonatal total 25(OH)D levels in the studies were low:
46% (case-cohort study) and 51% (case–control study) of in-
dividuals had 25(OH)D levels <25 nmol/l.
Conclusions/interpretation Our two large-scale national stud-
ies showed that 25(OH)D3 levels around the time of birth were
not associated with later type 1 diabetes risk. Whether higher
levels of 25(OH)D3 during pregnancy, acquired by higher
doses of supplementation than are recommended today in
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most countries, could protect the offspring against type 1 dia-
betes cannot be ruled out by the present studies.
Keywords Denmark . Gestation . Registers . Type 1
diabetes . VitaminD
Abbreviations
25(OH)D 25-Hydroxyvitamin D
CPR Unique personal identification number
CRS Danish Civil Registration System
DBS Neonatal dried blood spots
DanDiabKids Danish Childhood Diabetes Registry
DNSB Danish Newborn Screening Biobank
LC-MS Liquid chromatography–mass spectrometry
LLOQ Lower limit of quantification
Q1,Q3 Interquartile range (range between first and
third quartiles)
SDK Statistics Denmark
SSI Statens Serum Institute
Introduction
Type 1 diabetes is an organ-specific autoimmune disease with
a complex aetiopathogenesis [1]. Aworldwide annual increase
in incidence has been observed over the last three decades [2].
In-depth understanding of what triggers the autoimmune re-
sponse towards insulin-producing beta cells is not yet fully
clarified, but both genetic and environmental factors contrib-
ute. Since changes in the proportions of high-risk HLA genes
in a population are very slow (if there is any change at all), at
least a part of the factors that have led to a recent increase in
type 1 diabetes incidence are likely to be environmental expo-
sures or gene–environment interactions [3].
Vitamin D is a secosteroid with an intranuclear receptor
that functions as a transcription factor. The vitamin D receptor
is found in most human cells including cells of the immune
system and beta cells [4]. Inadequate vitamin D status is com-
mon among pregnant women and neonates [5], and in the
latter may influence disease susceptibility in childhood and
adolescence. Studies in mice have shown that gestational vi-
tamin D insufficiency and deficiency increase the penetrance
of type 1 diabetes [6]. Human observation and intervention
studies investigating the role of vitamin D status or vitamin D
supplementation during pregnancy in the risk of type 1 diabe-
tes in offspring have so far yielded conflicting results. Only a
few of these studies measured blood levels of 25-
hydroxyvitamin D (25(OH)D)—a biomarker of vitamin D
status [7–11].
Therefore, the aim of the present study was to examine
whether low levels of 25(OH)D at birth increase the risk of
developing type 1 diabetes before the age of 18 years in large-
scale studies using Danish national register data.Wemeasured
25(OH)D levels in neonatal dried blood spots (DBS)
consisting of capillary blood taken from nearly all neonates
in Denmark within a week after birth [12]. Here we report the
results of two studies simultaneously conducted by two dif-
ferent research groups.
Methods
Data sources
The Danish Civi l Regis t ra t ion System (CRS),
established in 1968, registers all persons in Denmark
alive on 2 April 1968 and born thereafter [13]. The
unique personal identification number (CPR) from the
CRS can be used for linkage with individual informa-
tion from a range of other routine administrative regis-
ters and large clinical databases in the country. The
Danish Childhood Diabetes Registry (DanDiabKids),
established in 1996, collects information on all
hospitalised incident cases of type 1 diabetes diagnosed
at age 15 years and below before 1 January 1996 (i.e.
born since 1981); since 2015 individuals diagnosed at
up to age 18 years are included [2]. For all cases re-
ported to the DanDiabKids, the original hospital records
are scrutinised to establish the validity of the diagnosis.
Statistics Denmark (SDK) maintains a large number of
national registers including the National Birth Registry,
the Family Register, the Population Education Register,
the Income Statistics Register, the Immigration and
Descendants Register, the Labor Market Register, the
Danish Prevention Register and the National Patient
Register [14]. Finally, the Danish Newborn Screening
Biobank (DNSB) at the Statens Serum Institute (SSI)
has stored neonatal DBS at −20°C (−4°F) since 1
May 1981 [12].
Assessment of vitamin D status
In both studies, vitamin D status was assessed by measuring
25(OH)D2 and 25(OH)D3 in 3.2 mm samples (also called
punches) taken from DBS cards. Sample preparation and
analysis was performed using liquid chromatography–mass
spectrometry (LC-MS) according to a modified version of
the analysis [15]. The modifications consisted of calibrations
conducted by using commercially available calibrators and
controls (Perkin Elmer, Waltham, MA, USA) and an online
extraction step. The LC-MS system consisted of an Aria
TLX2 system (Thermo Fisher Scientific, Waltham, MA,
USA) with two Agilent 1100 binary pumps and two Agilent
Quaternary pumps (Agilent, Santa Clara, CA, USA) connected
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to a Thermo TSQ Ultra triple quadrupole mass spectrometer
equipped with an electrospray ion source. Online extraction
was performed using a Cyclone P 0.5 mm×50 mm Turbo flow
column (Thermo Fisher Scientific) and analytical separation
was achieved using Hypersil gold 50 mm×2.1 mm, 3 μm
reversed-phase column (Thermo Fisher Scientific). To control
the quality of the analyses, Perkin Elmer’s MSMS Vitamin D
kit for mass spectrometry was used. Two sets of controls at
three different concentration levels were analysed before and
after project samples within each batch. In addition, native full
blood from a healthy volunteer was spotted onto filter paper and
analysed before and after project samples. All the controls were
set to be within 15% of the target value, otherwise the results
were rejected.
The lower limit of quantification (LLOQ) was 4 nmol/l
for 25(OH)D3 and 3 nmol/l for 25(OH)D2. The
25(OH)D levels from the DBS are full blood concentra-
tions. Most 25(OH)D molecules in the bloodstream are
protein bound and to approximate and report sera con-
centrations we corrected the original levels using the
formula: serum 25(OH)D= full blood 25(OH)D × (1 /
[1− 0.61]), where 0.61 is the haematocrit fraction for
capillary blood [16].
Study design, sample population and variables
Case-cohort study The case-cohort study included a random
subcohort of 3585 individuals from the CRS from among
1,360,466 individuals born in Denmark during 1981–2002,
and followed up until the end of 2012; during the follow-up
time, seven individuals had developed type 1 diabetes.
According to power calculations, 80% power and a sample
size of 1000 cases with type 1 diabetes would show a least
detectable HR of 1.15 related to 1 SD difference in 25(OH)D
with 60% variance explained by all the covariates [17]. As not
all DBS cards can be found in the DNSB, we randomly sam-
pled 1080 cases from the DanDiabKids among a total of 4404
in the register born in 1981–2002 and diagnosed until the end
of 2012; four of the sampled cases overlapped with the seven
type 1 diabetes cases from the random subcohort sample.
Inclusion and exclusion criteria are shown in Fig. 1a.
For the 4661 selected individuals, information on birth out-
comes, parent’s diabetes, maternal ethnicity and parent’s so-
cioeconomic position (i.e. education, employment, income,
savings) was collected from the SDK registers and linked with
the information on 25(OH)D concentrations. The Danish Data
Protection Agency gave permission for data retrieval and
a 
All individuals born in DK 
during 1981–2002 and 
followed up until the end of 
2012 from the CRS: 
1,360,466 
Individuals born in DK during 1981–2002 
developing T1D before age of 18 years, followed 
up until the end of 2012 from DanDiabKids: 
4404 
Random sub-cohort:  
3585 
- 7 individuals with T1D 
- 3578 individuals without T1D
Random sample of individuals with 
T1D:  
1080 
Individuals sampled for analyses: 
4661  
- 349 already punched (overlap with the case–
control study) 
- 4312 delivered to SSI to find DBS 
Individuals with a vitamin D result: 
3778
- 2873 from a random sub-cohort including 7 
T1D cases 
- 909 from a sample with T1D, including 4 cases 
overlapping with the sub-cohort cases (above) 
Excluded owing to unavailable 
vitamin D analysis result: 
883 
- 708 DBS not found 
- 94 analyses failed 
- 81 insufficient for analysis 
material  
Individuals without T1D: 
2866 (76%) 
Sampling probability for a non-case 
in all individuals without T1D:  
2866/1,356,062 
Individuals with T1D: 
912 (24%) 
Sampling probability for a T1D case 
in all individuals with T1D:  
912/4404 
Overlap 
4 individuals with T1Da
b 
Initially, 626 matched pairs were identified, 
born in DK during 1981–1999 and 
developing T1D before age of 18 years, 
followed up until 1 May 2004 
Successful 25(OH)D analysis: 
- 609 cases  
- 575 controls 
Failed in 25(OH)D analysis or 
missing unique identification 
number: 
- 17 cases 
- 51 controls 
527 matched pairs were available 
for inclusion in Model 1 without 
adjustment for HLA genotype 
Exclusion of seven controls 
owing to an autoimmune 
disease diagnosis: 
- 3 CD 
- 3 UC 
- 1 T1D 
Loss of matching and 
therefore exclusion: 
- 82 cases  
- 41 controls 
429 matched pairs were available 
for inclusion in Model 2 with 
adjustment for HLA genotype 
Missing values in minimum 
one HLA-DQB1 allele: 
- 63 cases  
- 51 controls 
Excluded owing to loss of 
matching:  
- 35 cases  
- 47 controls 
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Fig. 1 Flow charts for the case-cohort study (a) and case–control study (b). CD, Crohn’s disease; DK, Denmark; T1D, type 1 diabetes; UC, ulcerative
colitis. aAllocated to the sub-cohort for descriptive analyses, and to the pool of individuals with T1D for association analyses
merging (J. no.: 2012-41-41156). Permission to access and
analyse the DBS was granted by the Ethical Committee D of
the Capital Region of Denmark (J. no.: H-3-2011-126) and the
DNSB Steering Committee.
Case–control study The nested case–control study had a 1:1
matching. Power calculation showed that a sample size of 460
matched pairs was needed to demonstrate a decreased risk of
50%; OR was 0.67 for developing type 1 diabetes. Initially,
626 matched pairs were randomly selected for 25(OH)D
analysis from an already-collected material of DBS used in a
study conducted by the same research group and originally
comprising 2086 cases and 4172 controls [18]. In the original
study, type 1 diabetes cases were included if individuals met
the following criteria: (1) born between 1981 and 2002; (2)
diagnosed between 1 January 1981 and 1May 2004; (3) had a
DBS card present in the DNSB. Individuals were excluded if
the following criteria applied: (1) additionally diagnosed with
another diabetes type; (2) insufficient material remained on
the DBS card; (3) twin, triplet, etc., status (the latter represent-
ed 3% of the cohort). Controls were selected by collecting the
DBS card next to the case’s card in the DNSB [18], thereby
matching on date and therefore season of birth. In the random-
ly selected sample used in the present study, individuals were
born during 1981–1999, due to the fact that < 0.5% individ-
uals were born during 2000–2002 in the sample of the original
study.
Of the 626 selected matched pairs, 527 pairs had complete
information on birth outcomes and maternal age and ethnicity,
collected from the SDK registers. Additionally, we had infor-
mation on HLA-DQB1 genotype (HLA risk). Genotyping has
been described elsewhere [18] and HLA risk categorisation is
shown in Table 1. Inclusion and exclusion criteria are shown
in Fig. 1b. The study was approved by the Danish Ethical
Committee (H-4-2013-049) and by the DNSB Steering
Committee.
Overlap of type 1 diabetes cases between case-cohort
and case–control studies
Both our studies, even though conceived and conducted by
two different research groups, used the same national data
sources to sample study population. Consequently, 349 cases
with type 1 diabetes overlapped between the case-cohort and
the case–control study samples. Furthermore, all the punches
from DBS cards used in the case–control study were collected
already in 2007, and then stored at −20°C (−4°F) until recent
25(OH)D analysis [18]. Accordingly, the material used for the
analyses in the case-cohort study was mixed in terms of sam-
pling time: the punches from the overlapping 349 cases were
collected in 2007 and the remaining punches were newly col-
lected. While running the 25(OH)D assays, the punches of the
349 overlapping cases were distributed equally throughout all
of the microtitre plates and, hence, across different 25(OH)D
analysis times. This approach was used to minimise the risk of
confounding between biological and batch effects [19].
Statistical analysis
As also shown previously [20], a high percentage of the
25(OH)D2 levels were below the LLOQ (3 nmol/l): 91% in
the case-cohort study and 90% in the case–control study.
Therefore, the main analyses reported are for 25(OH)D3
levels. Sensitivity analyses were conducted for total
25(OH)D (i.e. 25(OH)D3+25(OH)D2).
Case-cohort study Descriptive data were presented as me-
dians with interquartile range (range between first quartile
and third quartile [Q1, Q3]), except for income statistics which
were expressed as means (SD). Unlike the classic case-cohort
design [21], only a sample of the type 1 diabetes cases from
the cohort of all children born between 1981 and 2002 was
included in the final analysis. Therefore the analysis was
based on sampling theory: to estimate the magnitude of effect
of 25(OH)D3 levels on the risk of type 1 diabetes, we used
Cox regression with the cases and non-cases in the final sam-
ple weighted by their inverse sampling probabilities [22]. The
standard errors of the estimated effects were computed by the
robust method [23]. Sampling probabilities for individuals
with and without type 1 diabetes are shown in Fig. 1a. To
better capture a potential non-linear association, the
25(OH)D3 levels were divided into quintiles based on the
concentrations of the random subcohort representing general
population levels. The regression model was pre-defined
based on literature and included the following confounders:
gestational and mother’s delivery ages, birthweight, mother’s
ethnicity and history of diabetes and parental socioeconomic
position at the time of an individual offspring’s birth [24, 25].
Additionally, the model was adjusted for previously reported
birth cohort effect in type 1 diabetes incidence increase in
Denmark, expressed as a linear variable of year of birth [26].
For sensitivity reasons, analyses were conducted additionally
including season in the models, coded as spring (March–
May), summer (June–August), autumn (September–
November) and winter (December–February), and using
season-specific cut-offs for 25(OH)D3 quintiles [27]. Further
sensitivity analyses were conducted in groups with 25(OH)D3
levels below and above 25 nmol/l, as well as in the groups of
type 1 diabetes incidence age below and above 5 years.
Possible interactions between 25(OH)D3 quintiles and sex
(Wald test) were examined. Descriptive statistics was calcu-
lated in SPSS Version 22 (IBM Corporation, New York, NY,
USA); regression models were run in Stata Version 14
(StataCorp, College Station, TX, USA).
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Table 1 Characteristics of the population in the two studies
Variable Case-cohort study Case–control study
Case Cohorta p valueb Case Control p valueb
Variable of main interest
25(OH)D level 0.24 0.61
Median, nmol/l 26.9 26.8 24.7 24.8
Q1, Q3, nmol/l 17.8, 41.3 16.5, 39.7 15.7, 36.6 15.7, 35.4
n 912 2873 527 527
% with levels above 50 nmol/l 14.8 13.5 10.3 9.6
% with levels below 25 nmol/l 45.5 45.6 51.2 51.0
25(OH)D3 level 0.08 0.51
Median, nmol/l 24.3 23.8 21.3 21.1
Q1, Q3, nmol/l 14.8, 38.8 13.5, 36.7 12.5, 33.1 12.0, 32.9
n 912 2873 527 527
25(OH)D3 level 0.38 0.83
Median, nmol/l 1.5 1.3 1.9 1.9
Q1, Q3, nmol/l 0.0, 3.7 0.0, 3.8 0.0, 5.0 0.0, 5.0
n 912 2873 527 527
Basic characteristics
Sex 0.24 0.20
Female, % 50.5 48.4 49.7 45.7
Male, % 49.5 51.6 50.3 54.3
n 912 2873 527 527
Age of onset 0.59 NA
Median, years 10.2 10.5 8.5 –
Q1, Q3, years 7.5, 12.5 5.1, 11.5 5.0, 11.4 –
n 912 7 527 –
Mother’s age at child’s birth 0.04 0.14
Median, years 28 28 28 27
Q1, Q3, years 26, 32 25, 32 25, 31 24, 31
n 912 2833 527 527
Pregnancy and birth
Gestational age 0.002 0.94
Median, weeks 40 40 40 40
Q1, Q3, weeks 39, 41 39, 41 39, 41 39, 40
n 907 2815 527 527
Birthweight 0.88 0.11
Median, kg 3.5 3.5 3.5 3.5
Q1, Q3, kg 3.2, 3.9 3.2, 3.9 3.2, 3.9 3.1, 3.8
n 911 2824 527 527
Ethnicity
Mother’s ethnicity <0.00 0.36
Danish, % 94.6 90.5 96.8 95.2
Other western, % 1.9 2.3 0.4 1.0
Other non-western, % 3.5 7.2 2.8 3.8
n 912 2850 527 527
Genetics
HLA risk groups NA <0.00
Highc, % – – 63.9 15.6
Moderated, % – – 21.2 25.6
Low/protectivee, % – – 14.9 58.8
n – – 429 429
Mother’s diabetesf 0.003 NA
Yes, % 6.8 4.4 – –
No, % 93.2 95.6 – –
n 912 2873 – –
Father’s diabetesf NA
Yes, % 4.6 0.2 – –
No, % 95.4 99.8 – –
n 912 2873 – –
Socioeconomic status
Mother’s educationg 0.06 NA
Elementary school, % 27.5 30.8 – –
Gymnasium/professional, % 49.5 47.7 – –
University, % 23.1 21.4 – –
n 885 2746 – –
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Case–control study Descriptive data were expressed as
median (Q1, Q3) and the measure of effect was OR in-
cluding 95% CI. Univariate and multivariate conditional
logistic regression analyses were performed to examine
the influence of 25(OH)D3 on odds of developing type 1
diabetes adjusted for possible confounders. 25(OH)D3
was modelled as a continuous variable and to capture a
possible non-linear relationship between 25(OH)D3 levels
and type 1 diabetes risk, we used quintiles based on the
whole sample population. The assumptions for logistic
regression were fulfilled. As in the case-cohort study,
the models were based on pre-defined literature-based
hypothesised associations between a confounder,
25(OH)D3 levels and type 1 diabetes risk. The following
confounders were included: gestational and mother’s de-
livery age, birthweight and mother’s ethnicity [24, 25].
Two adjusted models were generated—one with and one
without the HLA risk variable (Fig. 2). Sensitivity analy-
ses and interactions were conducted as described under
the case-cohort study. In addition, an interaction between
25(OH)D3 quintiles and HLA risk was also thought bio-
logically plausible and was therefore examined. All
analyses were performed using SAS Version 9.2 (SAS
Institute, Cary, NC, USA).
Table 1 (continued)
Variable Case-cohort study Case–control study
Case Cohorta p valueb Case Control p valueb
Mother’s job statusg <0.00 NA
Employed, % 77.1 73.5 – –
Unemployed, % 9.0 11.5 – –
Out of labour market, % 13.8 15.0 – –
n 910 2802 – –
Father’s job statusg <0.00 NA
Employed, % 93.0 89.4 – –
Unemployed, % 3.1 5.2 – –
Out of labour market, % 3.9 5.4 – –
n 901 2788 – –
Mother’s gross incomeh,i <0.00 NA
Mean, DKKh per year 90,853 84,387 – –
SD, DKKh per year 40,104 41,395 – –
n 912 2845 – –
Father’s gross incomeh,i 0.001 NA
Mean, DKKj per year 144,023 133,959 – –
SD, DKKj per year 109,218 7520 – –
n 907 2845 – –
Mother’s income from savingsh 0.01 NA
Mean, DKKj per year 3732 3529 – –
SD, DKKj per year 5538 6851 – –
n 912 2845 – –
Father’s income from savingsh 0.08 NA
Mean, DKKj per year 7152 6920 – –
SD, DKKj per year 16,356 34,145 – –
n 907 2814 – –
The case–control study was based on 527 matched pairs, although the HLA-DQB1 risk grouping was calculated using the 429 matched pairs with both
alleles genotyped
aDescriptive characteristics for all subcohort individuals, including seven cases with type 1 diabetes
bWhen making a comparison in the case-cohort study, the overlap of four individuals between subcohort and type 1 diabetes sample was allocated to the
subcohort; statistical tests used in both studies: χ2 test for categorical variables and Mann–Whitney U test for numerical variables
cHLA-DQB1 *allele_1/*allele_2: 03:02/99:99, 03:02/02, 06:04/03:02
dHLA-DQB1 *allele_1/*allele_2: 03:01/02, 06:03/03:02, 02/99:99, 06:04/02, 06:04/99:99, 03:01/03:02. 06:04/03:04
eHLA-DQB1 *allele_1/*allele_2: 06:02/03:02, 06:02/99:99, 06:02/02, 06:03/99:99, 03:01/99:99, 06:02/03:01, 06:03/03:01, 06:04/03:01, 06:03/02,
03:04/99:99, 03:04/02, 06:02/03:04, 99:99/99:99 (99:99 = remaining alleles)
f All diabetes diagnoses, excluding gestational, given in a hospital setting before the individual’s birth
g On 1 January in the year of the offspring's birth
h On 1 January in the year of the offspring's birth, adjusted for year 1981 prices/inflation
i Income including pension and taxes
j 1 Danish krone (DKK)= 0.13 Euro or 0.15 US dollars
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Results
In the case-cohort study, the median (Q1, Q3) for
25(OH)D3 was 23.8 (15.5, 36.7) nmol/l in individuals
from the subcohort and 24.3 (14.8, 38.8) nmol/l in cases
with type 1 diabetes. In the case–control study, the
values were 21.1 (12.0, 32.9) nmol/l for controls and
21.3 (12.5, 33.1) nmol/l for cases. Total 25(OH)D,
25(OH)D3 and 25(OH)D2 levels did not differ between
the subcohort and cases or between the controls and
cases in the respective studies. Notably, 91% of
25(OH)D2 and 15% of 25(OH)D3 concentrations were
below the LLOQ in the case-cohort study; respective
values in the case–control study were 90% and 19%.
A trend of a slight increase in 25(OH)D3 concentrations
over years was observed in the case-cohort study:
β (95% CI) = 0.02 (0.00, 0.04), p < 0.001 (ESM
Fig. 1). All the characteristics of the sample population
in both studies are presented in Table 1.
Case-cohort study
We found no association between the quintiles of 25(OH)D3
concentrations and type 1 diabetes risk either in the main
adjusted analysis (Fig. 2) or in any of the sensitivity analyses
(data not shown). The interaction between sex and 25(OH)D3
quintiles was not significant. Additionally, we found that ges-
tational age (per week) (HR [95% CI] 0.96 [0.93, 1.00]),
mother’s diabetes status (diabetes vs no diabetes) (1.67
[1.20, 2.33]) and ethnicity (non-western vs Danish) (0.39
[0.25, 0.61]) were associated with type 1 diabetes risk. As
expected, birth cohort effect showed an increase in type 1
diabetes incidence over years (Fig. 2).
Fig. 2 Association between the quintiles of 25(OH)D3 concentrations
and type 1 diabetes risk. aQuintile values for 25(OH)D3 (nmol/l) in the
case-cohort study were as follows: first quintile (Q1) 0–11.92; second
quintile (Q2) 11.92–19.58; third quintile (Q3) 19.58–28; fourth quintile
(Q4) 28–40.79 and fifth quintile (Q5) 40.79–130.34. Quintile values for
25(OH)D3 (nmol/l) in the case–control study were as follows: Q1 0–
10.62; Q2 10.62–17.35; Q3 17.35–25.25; Q4 25.25–36.10 and Q5
36.10–117.91. bOR estimate and 95% CIs are outside range of visualisa-
tion. The shaded grey area captures the overlap of variables between the
two studies
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Case–control study
We found no association between 25(OH)D3 around time of
birth and type 1 diabetes risk in the adjusted models, either
when modelling 25(OH)D3 as a continuous variable in model
1 (excluding HLA risk: OR [95% CI] [per 25 nmol/l increase]
1.02 [0.80, 1.28]) and model 2 (including HLA risk: OR [95%
CI] [per 25 nmol/l increase] 0.86 [0.60, 1.22]) or when quin-
tiles were used (Fig. 2). Sensitivity analyses yielded essential-
ly identical results (data not shown). Interactions between sex,
HLA risk and 25(OH)D3 quintiles were not significant (data
not shown). Additionally, HLA risk was significantly associ-
ated with type 1 diabetes risk. A birthweight below 2500 g
was related to a decreased risk of type 1 diabetes when com-
pared with a birthweight of 2500–4499 g, but this association
was only seen in model 1 (excluding HLA risk).
Discussion
The present study examined relations between neonatal
25(OH)D3 levels and the risk of developing type 1 diabetes
before the age of 18 years. We did not observe an association
in either of two large-scale studies, using measured neonatal
25(OH)D3 levels and validated complete registry-based diag-
nosis of type 1 diabetes. While several of the previous studies
in this field relied on maternal self-reported dietary intake of
vitamin D, or on vitaminD supplementation during pregnancy
[8, 11], only two studies so far have examined maternal serum
25(OH)D concentrations [9, 10] and one study looked at the
25(OH)D3 levels in neonatal blood from DBS [7]. Results
from these three studies were conflicting: two found, like us,
no support for an association [7, 9] and one found that lower
maternal levels of serum 25(OH)D, measured late in the third
trimester, were associated with an increased risk of developing
type 1 diabetes in the offspring [10]. The three previous stud-
ies were all case–control studies. Importantly, our studies were
large-scaled and population-based with limited influence of
selection bias possible in the other Nordic studies [9, 10].
Similarly to the other studies, we used a validated and com-
plete registry for type 1 diabetes diagnosis, as well as a vali-
dated and reliable 25(OH)D assay. For comparison, the basic
information from all previous studies is presented in Table 2.
The neonatal screening samples that were used in our studies
showed notably lower 25(OH)D concentrations compared with
the levels found in other Nordic studies based on maternal
serum [9, 10]. This is in accordance with the results of the
studies comparing 25(OH)D3 levels in pregnant women and
in cord blood [5, 28]. The Norwegian study reported a
25(OH)Dmaternal mean level of 41 nmol/l vs cord blood mean
level of 31 nmol/l [28] and the Dutch study reported a 25(OH)D
maternal mean level of 51 nmol/l vs cord blood mean level of
32 nmol/l [5]. Further, we assayed levels in DBS, while the
Norwegian [10] and Finnish [9] studies assayed levels in serum.
The latter has ‘traceable standards’ from the National Institute
of Standards and Technology, while assays using DBS rely on a
range of other methods to calibrate for accuracy, and there is no
referencematerial or gold standardmethod to assess the validity
of the values from DBS sample analyses [16]. Despite the dif-
ferences in assay techniques, 25(OH)D concentrations from
DBS assays have been shown to correlate with those using cord
blood [16] and plasma [29] if the correction for haematocrit
fraction is used, as was done in our studies. Thus, we have no
reason to believe that the ranking of individuals with respect to
neonatal 25(OH)D levels in our studies was compromised.
We also compared 25(OH)D3 concentrations in our studies
with those reported by McGrath et al, measured from DBS in
the Danish population-based sample comprising 848 individ-
uals born in 1981–1994 [20]. The 25(OH)D3 concentrations
reported in the study byMcGrath et al were slightly higher than
in our studies: median (Q1, Q3) was 32.3 (20.5, 46.6). Notably,
the assays referred to by McGrath et al were run in another
laboratory, where the extraction and derivatisation techniques
were the same. The main difference was that McGrath et al
prepared calibrators through standard addition to native whole
blood, whereas our studies were based on purchased calibra-
tors from a commercial vendor. The difference in calibrators
may lead to a systematic difference in absolute levels but this,
if true, would not interfere with the reliability of the results on
reported associations. Moreover, while comparing the
25(OH)D3 results coming from different analysis settings, total
variation in the entire analysis sample should be considered.
Total variation in the analyses of our entire sample, including
the samples from both studies, was 15%. Thus, the 25(OH)D3
levels in our studies differed from those reported by McGrath
et al only by a few nmol/l (i.e. 25/27 nmol/l ±15%), which is
acceptable taking into account different calibration methods.
Considering biochemical aspects, the 25(OH)D concentra-
tions reported in the Norwegian study [10] still seem to be
higher than those found in our studies and in the Finnish study
[9]. This corresponds with the findings from previous large-
scale studies on 25(OH)D concentrations in pregnant women
in Nordic countries. The NorwegianMother and Child Cohort
Study found a 25(OH)D mean level of 74 nmol/l in mid-
pregnancy [30] whereas the Danish Odense Child Cohort
study revealed a median mid-pregnancy level of 66 nmol/l
[31]. The use of cod-liver oil by pregnant women in Norway
[32] could potentially contribute to the observed relatively
higher 25(OH)D levels. Consequently, the difference in find-
ings between our study and that of Miettinen et al [9] vs
Sørensen et al [10] may be due to a difference in 25(OH)D
concentrations in the studied populations. This further sug-
gests that higher levels of 25(OH)D are necessary to exert a
protective effect against type 1 diabetes in a complex exposure
network and that the higher levels may be potentially reached
by supplementation. Similarly, Hypponen et al [33] showed
1878 Diabetologia (2016) 59:1871–1881
that high-dose vitamin D supplementation (up to 50 μg daily)
in infancy reduced type 1 diabetes risk later in life by 80%.
Despite the possibly higher 25(OH)D levels in pregnant
women in Norway, type 1 diabetes incidence rates in Norway
are higher than inDenmark: 23–33 per 100,000 person-years vs
20–22 per 100,000 person-years, respectively [2, 34]. Clearly,
type 1 diabetes is a multifactorial disease and variations in
incidence rates between different countries are caused by sev-
eral factors. In the case-cohort study, maternal diabetes diagno-
sis, ethnicity and gestational age were associated with type 1
diabetes risk. A lower risk with increasing gestational age has
been also reported previously [24]. The increased risk for those
with diabetes in first-degree relatives has been reported previ-
ously as well [3]. Type 1 diabetes risk in the offspring of
mothers with a non-western minority background was lower,
despite lower levels of neonatal 25(OH)D. The only consistent
association in the case–control study was between HLA risk
group and type 1 diabetes risk, as shown previously using the
same material [18].
A child with a high load of type 1 diabetes susceptibility
genes may be more vulnerable to low levels of 25(OH)D
than a child with a neutral or protective genotype. In the
case-cohort study, to consider genetic susceptibility, we
made an attempt to adjust for maternal and paternal type 1
diabetes status, which accounts for both HLA and non-
HLA risk genes. Maternal diabetes status was shown to be
an important predictor of type 1 diabetes hazard in the off-
spring but it did not change the association between disease
risk and neonatal 25(OH)D3 levels. The number of individ-
uals whose fathers had diabetes was too low to provide
meaningful results. In the case–control study, adjusting
for HLA risk did not change the results either and the
case–control study was the first and so far the only study
adjusting for HLA risk in the neonatal 25(OH)D3 and type 1
diabetes risk association. The case–control study was un-
able to adjust for non-HLA genetic susceptibility, which
would require a very large sample size due to small effects
by these numerous gene variants [3].
Table 2 Main information from the studies assessing association between pregnancy or neonatal 25(OH)D levels and risk of type 1 diabetes
Variable Sørensen et al 2012
(Norway) [10]
Miettinen et al 2012
(Finland) [9]
Cadario et al
2015 (Italy) [7]
Case-cohort,
2016 (Denmark)
Case–control,
2016 (Denmark)
25(OH)D measurement, timing Serum, pregnancy
third trimester
Serum, pregnancy
first trimester
Neonatal,
third day
Neonatal,
first–third day
Neonatal, first–
third day
Population size
Cases 109 343 67 912 527
Controls or cohort 209 343 236 2873 527
Sampling National cohort, women
who gave consent
Register based, women
who accepted invitations
Register based,
random
sample
Register based,
random
sample
Register based,
random
sample
Serum 25(OH)D, mean (SD)
or median (Q1, Q3)
Offspring or individuals
with T1D
65.8 (26.5) 43.9 (16.9) – 26.9 (17.8, 41.3) 24.8 (15.7, 35.4)
Offspring or individuals
without T1D
73.1 (27.2) 43.5 (16.6) – 26.8 (16.5, 36.7) 21.1 (12.0, 32.9)
Serum 25(OH)D3, geometrical
meana or median (Q1, Q3)
Offspring or individuals
with T1D
– – 1.42 24.3 (14.8, 38.8) 21.3 (12.5, 33.1)
Offspring or individuals
without T1D
– – 1.81 23.8 (13.5, 36.7) 21.1 (12.0, 32.9)
T1D cases’ year of birth 1992–1994 1993–2000 1992–2012 1981–2002 1981–1999
T1D incidence periods 1992–2009 1993–2007 2002–2012 1981–2012 1981–2004
T1D incidence age in years
Mean or mean (SD) 9.0 (3.6) 3.4 4.2 (3.4) – –
Median (Q1, Q3) – – – 10.2 (7.5, 12.5) 8.5 (5.0, 11.4)
Range 0–15 0–7 0–10 0–18 0–18
Association between 25(OH)D
and T1D risk, OR
(95% CI), adjusted Q1 vs Q4
2.38 (1.12, 5.07) NS NS NS NS
T1D, type 1 diabetes; Q4, fourth quartile; NS not significant association
a Geometrical means in our studies was in the range of 1.1
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Interestingly, a tendency towards yearly increase in
25(OH)D3 levels was observed in the case-cohort study
(ESM Fig. 1). The observed increase in 25(OH)D3 concentra-
tions may have been caused by an increase in the number of
hours of sunshine in Denmark [35] and/or by an increase in
vitamin D intake through supplementation possibly due to a
change in vitamin D-related awareness in the public.
Additionally, decreased prevalence of smoking (negatively
affecting 25(OH)D concentrations [36]) among pregnant
women in Denmark may have contributed to the observed
differences. On the other hand, due to the wide distribution
of values throughout the years, the observed trend in
25(OH)D3 increase may be a spurious result. To take into
account the possibility of 25(OH)D changes over years (and
simultaneously consider increase in type 1 diabetes incidence
rates over years in Denmark), all the analyses in the case-
cohort study were adjusted for year of birth expressed as a
linear variable.
Our studies were based on hypotheses of gestational pro-
gramming, in this particular case claiming that low levels of
25(OH)D during periods of immune system maturation may
cause long-term irreversible effects on immunological health
[37]. It can be argued that one 25(OH)D measurement at a
specific time-point (i.e. at birth) may not mirror earlier
25(OH)D pregnancy levels. Because the fetus is completely
dependent on maternal 25(OH)D supply [38] and because the
half-life of 25(OH)D is approximately 2–3 weeks [39], the
25(OH)D levels at birth, as a minimum, reflects fetal
25(OH)D exposure during the end of third trimester of preg-
nancy. At the same time, immune maturation is especially
prominent with regards to development of self-tolerance from
mid-pregnancy [40].
In conclusion, our two nationwide large-scale studies
showed that 25(OH)D3 levels around the time of birth were
not associated with type 1 diabetes risk. We cannot rule out
whether higher levels of 25(OH)D3 during pregnancy,
acquired by higher doses of supplementation than those rec-
ommended in Nordic countries today (10 μg daily), may pro-
tect the offspring against type 1 diabetes. Likewise, the possi-
bility that 25(OH)D3 levels during the first and second trimes-
ters of pregnancy could be associated with later risk of type 1
diabetes cannot be ruled out either.
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